Phase II prospective trial “Give Me Five” short-term high precision radiotherapy for early prostate cancer with simultaneous boost to the dominant intraprostatic lesion: the impact of toxicity on quality of life (AIRC IG-13218)
Sign Up to like & getrecommendations! Published in 2020 at "Medical Oncology"
DOI: 10.1007/s12032-020-01397-3
Abstract: As part of the AIRC IG-13218 (NCT01913717), we analyzed data from patients with low- and intermediate-risk prostate cancer treated with extreme hypofractionated radiotherapy (RT) and simultaneous boost to the intraprostatic lesion. The aim of the… read more here.
Keywords: prostate; intraprostatic lesion; toxicity; cancer ... See more keywords
Simultaneous Integrated Radiotherapy Boost to the Dominant Intraprostatic Lesion: Final Results of a Phase I/II Trial
Sign Up to like & getrecommendations! Published in 2020 at "AntiCancer Research"
DOI: 10.21873/anticanres.14672
Abstract: Background/Aim: Late toxicity and long-term outcomes of a phase I-II trial on patients with prostate cancer treated with an integrated boost to the dominant intraprostatic lesion (DIL) are reported. Patients and Methods: Patients were treated… read more here.
Keywords: intraprostatic lesion; boost; toxicity; boost dominant ... See more keywords